Clinical Trials
136 trialsROXI-CAT-I
Regeneron Pharmaceuticals
VICTORIE
Pfizer
STAT-CAT
Brigham and Women's Hospital
PINPOINT
University of Dublin, Trinity College
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Memorial Sloan Kettering Cancer Center
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Beijing Chao Yang Hospital
MAGNOLIA
Anthos Therapeutics, Inc.
Apixaban in Thrombocytopenia
Beth Israel Deaconess Medical Center
Glioblastoma Remote Monitoring and Care - Research Protocol
Case Comprehensive Cancer Center
ROXI-CAT-II
Regeneron Pharmaceuticals
AVAJAK
University Hospital, Brest
AmiCARE
Shanghai Pulmonary Hospital, Shanghai, China
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
The First Hospital of Jilin University
ASTER
Anthos Therapeutics, Inc.
DOAC
University of Vermont
CATIQ P3
Quercis Pharma AG
ASPIRE
Wake Forest University Health Sciences
VTE-POG
University of Vermont Medical Center
CLOVER
Infanta Leonor University Hospital
HEM-DOAC
Medical University of Gdansk
Implementing VTE Prevention in Ambulatory Cancer Care
University of Vermont
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
University Of Perugia
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
State University of New York - Upstate Medical University
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Massachusetts General Hospital
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
Chang Gung Memorial Hospital
MYELAXAT
University Hospital, Grenoble
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
Medical University of South Carolina
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PREVENT-GU
Ottawa Hospital Research Institute
TRIM-Line
Ottawa Hospital Research Institute
CARAVAGGIO
Fadoi Foundation, Italy
BRAVE-Cyclin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
STREAM-Line
Ottawa Hospital Research Institute
CARDIO-COM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
LEO Pharma
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
IRCCS Azienda Ospedaliero-Universitaria di Bologna
GynCAT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Multicenter, Open-Label, Non-Inferiority Randomized Controlled Trial of Postoperative VTE Prevention in Chinese Patients After Colorectal Cancer Surgery
Beijing Friendship Hospital
Evaluating the Risk of Postoperative Venous Thromboembolism in Cervical Cancer Patients
Chongqing University Cancer Hospital
AIRPORT-MPN
Ottawa Hospital Research Institute
CONTEST
University of Aarhus
LIFE - Lung Cancer, Immunotherapy, Frailty, Effect
University of Southern Denmark
ROSIE
Radboud University Medical Center
Risk Factors of Venous Thromboembolism After Colorectal Cancer Surgery
Pirogov Russian National Research Medical University
WAVe
Ottawa Hospital Research Institute
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Nanfang Hospital, Southern Medical University
PaTR-VTE
University of Thessaly
Cancer Associated Thrombosis : What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO
Centre Hospitalier Universitaire de Saint Etienne
CANVAS
Alliance Foundation Trials, LLC.
APEX
Alexion Pharmaceuticals, Inc.